2 May 2026

FDA's proposed 503B GLP-1 exclusion is a different regulatory action (GLP-1 compounding, not peptide reclassification) but reveals career staff actively exercising oversight on compounding. Tangential to PCAC but consistent with institutional conservatism. 82 days to PCAC. Zero vacancy appointments in 10 weeks.

Same vacancy dynamics. The Augur notes an interesting institutional tension: FDA simultaneously cracking down on GLP-1 compounding while considering opening peptide compounding. Could be a managed transition — close one door, open another — but this is speculative. 82 days to meeting.

9 days to May 11 Q1 earnings. FDA 503B GLP-1 exclusion strengthens Hims's branded Novo deal but does not directly impact the peptide launch thesis. Analyst EPS expected $0.06 (down 70% YoY). Watch for peptide timeline specifics and California facility capex commentary.

FDA 503B GLP-1 exclusion could push some outsourcing facilities to pivot into peptide compounding if their GLP-1 business is eliminated — a marginal increase in contamination risk, but speculative. No new adverse events. No named victim. Journalistic templates remain positioned.

503B exclusion further restricts compounded GLP-1 alternatives, potentially increasing Bridge demand pressure. But structural enrollment friction (central processor, prior auth, $50 copay not counting toward OOP cap) is unchanged. 60 days to July 1 launch. Medicaid BALANCE state sign-ups in May are the leading indicator.

503B exclusion entrenches branded GLP-1 revenue pathways. Math unchanged ($260 CPA vs $8–40).

90 days remain. Market demand signals growing on both build candidates — HRT comparison (shortage intensifying, prescriptions doubled) and GHK-Cu (confirmed $370M market). Execution-dependent. No build progress data.